Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 2/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4505757 | 0.93 | PGR (0.48) | ALDH1A1KMT2AGAAPKML3MBTL1 | |
| SCHEMBL4488977 | 0.92 | MAPT (0.42) | ALDH1A1KMT2AGAAPGRNR3C1 | |
| SCHEMBL4491425 | 0.92 | FLT1 (0.47) | ALDH1A1KMT2AGAAPKML3MBTL1 | |
| SCHEMBL4496378 | 0.90 | MAPT (0.51) | ALDH1A1KMT2AGAAPGRNR3C1 | |
| SCHEMBL4492694 | 0.89 | MAPT (0.41) | ALDH1A1KMT2AMAPTSMN1; SMN2TP53 | |
| SCHEMBL4497264 | 0.89 | ALDH1A1 (0.44) | ALDH1A1KMT2AGAAPKML3MBTL1 | |
| SCHEMBL4494987 | 0.88 | ALDH1A1 (0.47) | ALDH1A1KMT2AGAAMAPTSMN1; SMN2 | |
| SCHEMBL4500266 | 0.87 | CNR1 (0.39) | ALDH1A1KMT2APGRNR3C1MAPT | |
| SCHEMBL4507017 | 0.87 | ALDH1A1 (0.41) | ALDH1A1KMT2AGAAPKML3MBTL1 | |
| SCHEMBL4499994 | 0.86 | GSR (0.45) | ALDH1A1KMT2AMAPTPOLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589120-B2 | N-[(4,5-diphenyl-2-thienyl)methyl]sulfonamide derivatives, preparation thereof and their therapeutic application | SANOFI-AVENTIS (FR) | 2009-09-15 | — | — | US | claimed |
| US-20070287744-A1 | N-[(4,5-DIPHENYL-2-THIENYL)METHYL]SULFONAMIDE DERIVATIVES, PREPARATION THEREOF AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2007-12-13 | — | — | US | claimed |
| EP-1841754-A1 | N-[(4,5-DIPHENYL-2-THIENYL)METHYL]SULFONAMIDE DERIVATIVES, PREPARATION THEREOF AND THEIR THERAPEUTIC APPLICATION | Sanofi-Aventis (FR) | 2007-10-10 | — | — | EP | claimed |
| WO-2006077320-A1 | N-[(4,5-DIPHENYL-2-THIENYL)METHYL]SULFONAMIDE DERIVATIVES, PREPARATION THEREOF AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2006-07-27 | — | — | WO | claimed |
| US-7589120-B2 | N-[(4,5-diphenyl-2-thienyl)methyl]sulfonamide derivatives, preparation thereof and their therapeutic application | SANOFI-AVENTIS (FR) | 2009-09-15 | — | — | US | disclosed |
| US-20070287744-A1 | N-[(4,5-DIPHENYL-2-THIENYL)METHYL]SULFONAMIDE DERIVATIVES, PREPARATION THEREOF AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2007-12-13 | — | — | US | disclosed |
| EP-1841754-A1 | N-[(4,5-DIPHENYL-2-THIENYL)METHYL]SULFONAMIDE DERIVATIVES, PREPARATION THEREOF AND THEIR THERAPEUTIC APPLICATION | Sanofi-Aventis (FR) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006077320-A1 | N-[(4,5-DIPHENYL-2-THIENYL)METHYL]SULFONAMIDE DERIVATIVES, PREPARATION THEREOF AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287744-A1 | N-[(4,5-DIPHENYL-2-THIENYL)METHYL]SULFONAMIDE DERIVATIVES, PREPARATION THEREOF AND THEIR THERAPEUTIC APPLICATION | TPMT, TXNRD2, ARG2 | ALDH1A1 385/4885KMT2A 1401/4885GAA 2714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.